TVTX Q1 2026: Filspari Revenue Jumps 88% as FSGS Approval Unlocks $3B Peak Sales Path
Trevier Therapeutics delivered a pivotal quarter, securing the first full FDA approval for Filspari in FSGS and driving record demand in IgA nephropathy. The company’s commercial execution and pipeline momentum position it for sustained rare disease leadership, with Filspari’s dual indications now targeting over 100,000 eligible U.S. patients. Management’s focus on rapid FSGS uptake and disciplined investment signals a shift toward accelerating top-line growth and long-term value creation.
Summary
- FSGS Approval Expands Market: Filspari’s label expansion positions TVTX for rare disease category leadership.
- Commercial Execution Drives Uptake: Record new patient starts and payer access signal accelerating adoption in both indications.
- Pipeline Progression Sustains Growth: Harmony Phase 3 restart and peak sales outlook reinforce multi-year growth trajectory.
Performance Analysis
Trevier’s first quarter marked a strategic inflection, with Filspari, its non-immunosuppressive kidney therapy, now fully approved for FSGS (focal segmental glomerulosclerosis, a rare, progressive kidney disease) and continuing to gain ground in IgA nephropathy. Filspari revenue soared 88% year-over-year to $105.2 million, despite typical Q1 insurance headwinds and one fewer shipping week, confirming robust underlying demand. The company reported 993 new patient start forms, a record that underscores both new prescriber expansion and increased adoption within established nephrology practices.
Management highlighted that payer access for FSGS is building on the foundation set by IgA nephropathy, with over 97% of patients having a pathway to coverage. SG&A and R&D expenses increased, reflecting investments in the FSGS launch and the restart of the pivotal Harmony study for pegtobatinase, a novel enzyme therapy in classical homocystinuria (HCU, a rare metabolic disorder). The company’s cash position remains strong, with $352 million in liquidity, supporting ongoing commercial and late-stage clinical initiatives.
- Filspari Demand Outpaces Supply Timing: Revenue recognition lags patient demand due to logistics, setting up Q2 for catch-up growth.
- SG&A and R&D Scale with Opportunity: Cost increases are targeted at commercial expansion and pipeline progression, not structural inefficiency.
- Non-GAAP Profitability Achieved: Adjusted net income turned positive, reflecting operational leverage as revenue scales.
Commercial metrics and disciplined capital allocation suggest TVTX is transitioning from a single-product story to a rare disease platform with expanding addressable markets.
Executive Commentary
"Achieving the first full FDA approval for Filspari in FSGS established it as the first and only approved medicine for this rare and devastating kidney condition. With the potential to help more than 30,000 people living with FSGS without nephrotic syndrome, this approval is a significant indication expansion for Filspari and meaningfully increases the opportunity ahead for us."
Dr. Eric Dube, President and Chief Executive Officer
"We delivered another strong quarter of execution across the business. Importantly, U.S. net product sales at Filspari grew approximately 88% year-over-year to $105.2 million, despite typical beginning-of-year gross net impact and fewer revenue recognition days. We are well-positioned to fund our operations with existing resources and expect continued strong demand and hygiene of property to drive sustained revenue growth, with FSGS further contributing to our top-line trajectory."
Chris Klein, Chief Financial Officer
Strategic Positioning
1. Filspari’s Dual Indication Platform
The FDA’s full approval of Filspari for FSGS creates a first-mover advantage in a high unmet need segment, with the drug now uniquely positioned as the only approved therapy for both IgA nephropathy and FSGS. Management estimates more than 100,000 U.S. patients are eligible, with a $3 billion peak sales opportunity. The overlap in prescriber base and payer access between the two indications enables rapid leverage of existing commercial infrastructure.
2. Accelerated FSGS Launch Dynamics
Early FSGS launch signals point to faster uptake than the original IgA nephropathy rollout, driven by high physician awareness, urgent clinical need, and established payer coverage. The field team’s experience and the “halo effect” from IgA prescribers are accelerating adoption, with first patient start forms and reimbursement approvals arriving within days of approval.
3. Pipeline Progression with Harmony Study
The restart of the Phase 3 Harmony study for pegtobatinase in HCU adds a third potential rare disease pillar, with top-line data expected in the second half of 2027. Pegtobatinase aims to be the first disease-modifying therapy for HCU, targeting a global addressable population of 7,000 to 10,000 patients. The program is supported by rapid, sustained homocysteine reduction data from earlier studies.
4. Commercial Execution and Market Development
Record new patient starts and high conversion rates reflect deepening physician confidence and robust patient persistence, with discontinuation rates remaining low and aligned with clinical trial experience. The market for kidney disease therapies remains underpenetrated, and Filspari’s foundational nephroprotective profile is driving category expansion rather than share shift from competitors.
5. Capital Allocation and Cost Transparency
SG&A and R&D investments are tightly linked to revenue growth and pipeline milestones, with new royalty expense reporting providing greater clarity on underlying operating costs. The company’s cash reserves and milestone receipts provide runway for continued execution without near-term financing risk.
Key Considerations
This quarter’s results reflect a company in strategic transition, moving from single-product execution to a platform approach in rare nephrology and metabolic disease. The FSGS approval and rapid launch are pivotal, but sustaining momentum requires flawless execution and ongoing education of physicians and payers.
Key Considerations:
- FSGS Launch Velocity: Early uptake and payer approvals are tracking ahead of prior launches, but education on label nuances remains critical for broad adoption.
- Prescriber Overlap and Halo Effect: Existing IgA nephropathy prescribers are accelerating FSGS adoption, with a reciprocal effect expected as new FSGS prescribers begin to use Filspari in both indications.
- Competitive Landscape Evolution: New entrants in IgA nephropathy are expanding the market, but Filspari’s foundational positioning and real-world persistence rates reinforce its leadership.
- Pipeline Execution Risk: Harmony study progress is essential for future growth, with regulatory alignment and patient enrollment as key milestones to monitor.
Risks
Key risks include execution missteps in the FSGS launch, slower-than-expected physician education on label criteria, and potential competitive inroads from new kidney disease therapies. Pipeline risk remains, particularly for pegtobatinase, where regulatory endpoints and enrollment pace could alter the long-term growth narrative. Cost discipline will be tested as SG&A and R&D scale with new launches and late-stage trials.
Forward Outlook
For Q2 2026, Trevier guided to:
- Continued acceleration in Filspari demand across both IgA nephropathy and FSGS, with Q1 shipment timing expected to benefit Q2 revenue.
- Expansion of payer coverage and prescriber base in FSGS, leveraging existing infrastructure.
For full-year 2026, management maintained its focus on:
- Filspari revenue growth in both indications, targeting the >100,000 patient opportunity.
- Advancement of the Harmony Phase 3 trial with top-line data expected in 2027.
Management emphasized the durability of demand, operational discipline, and confidence in meeting both near-term and long-term growth objectives.
Takeaways
Trevier’s Q1 results mark a step-change in scale and opportunity, with Filspari’s dual-indication momentum and pipeline progression underpinning a multi-year growth story.
- FSGS Approval Unlocks Growth: Filspari’s new label and rapid uptake position TVTX as a leader in rare kidney disease, with a clear path to $3 billion peak sales.
- Commercial and Operational Execution: Record demand, robust payer access, and strong prescriber confidence drive sustainable growth, while cost discipline supports profitability.
- Pipeline and Market Development: Harmony study and ongoing market education will be critical to sustaining momentum and defending category leadership against new entrants.
Conclusion
Trevier Therapeutics’ Q1 2026 results reflect a company at a strategic inflection, with Filspari’s expanded indications and pipeline advancement setting the stage for durable, multi-indication growth. Investors should monitor FSGS launch velocity, pipeline milestones, and evolving competitive dynamics as key drivers of long-term value.
Industry Read-Through
The rapid FSGS approval and launch underscore the value of first-mover advantage in rare disease markets, with payer access and prescriber education as critical levers. The evolving kidney disease treatment landscape is shifting toward combination, foundational therapies, and non-immunosuppressive options. Competitors in nephrology and metabolic rare disease should note the importance of label clarity, real-world persistence, and the ability to leverage commercial infrastructure across indications. Market expansion, not just share shift, is driving growth—pointing to a multi-product, multi-segment playbook as the new standard for rare disease biotechs.